Want to see INBX full AI Analyst Report?
Inhibrx Biosciences Inc (INBX) Financial Statements
Inhibrx Biosciences Inc Financial Overview
Inhibrx Biosciences Inc's market cap is currently $1.06B. The company's EPS TTM is $-8.88; its P/E ratio is -8.08; and it has a dividend yield of 5.23%. Inhibrx Biosciences Inc is estimated to report earnings on November 13, 2026, and the estimated EPS forecast is $-2.45. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 1.30M | $ 200.00K | $ 1.80M | $ 2.19M | $ 7.13M |
| Gross Profit | $ -1.18M | $ -2.08M | $ 609.00K | $ -107.99M | $ 4.44M |
| Operating Income | $ -135.03M | $ -331.45M | $ -219.22M | $ -129.12M | $ -76.67M |
| EBITDA | $ -125.37M | $ 1.70B | $ -206.69M | $ -125.82M | $ -75.36M |
| Net Income | $ -140.06M | $ 1.69B | $ -241.36M | $ -145.23M | $ -81.77M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 124.22M | $ 152.60M | $ 277.92M | $ 273.87M | $ 131.30M |
| Total Assets | $ 146.48M | $ 180.77M | $ 307.89M | $ 290.88M | $ 150.45M |
| Total Debt | $ 107.01M | $ 8.05M | $ 210.14M | $ 207.10M | $ 72.14M |
| Net Debt | $ -17.21M | $ -144.55M | $ -67.78M | $ -66.76M | $ -59.16M |
| Total Liabilities | $ 138.49M | $ 47.18M | $ 264.39M | $ 232.82M | $ 98.07M |
| Stockholders' Equity | $ 7.99M | $ 133.58M | $ 43.50M | $ 58.06M | $ 52.38M |
| Cash Flow | |||||
| Free Cash Flow | $ -129.82M | $ -197.01M | $ -197.90M | $ -115.99M | $ -81.19M |
| Operating Cash Flow | $ -129.79M | $ -194.41M | $ -193.31M | $ -115.30M | $ -80.32M |
| Investing Cash Flow | $ -28.00K | $ -2.60M | $ -4.59M | $ -686.00K | $ -809.00K |
| Financing Cash Flow | $ 101.45M | $ 71.68M | $ 201.96M | $ 258.55M | $ 83.77M |
Currency in USD